Ferrous Sulfate

Introduction Overview

Generic Name

ferrous sulfate

Brand Name

FeroSul

Dosage Form

Oral tablet, Oral liquid

Drug Class

Iron products

Pharmacokinetics

Absorption:
Ferrous sulfate is primarily absorbed in the duodenum and upper jejunum through an active transport mechanism that is dependent on the body's iron stores and the acidity of the gastrointestinal tract. Optimal absorption occurs under acidic conditions; hence, it is recommended to take ferrous sulfate on an empty stomach to enhance bioavailability. Food and antacids can significantly impair absorption by increasing gastric pH or forming insoluble complexes. The oral bioavailability of ferrous sulfate ranges approximately between 10% to 15% depending on dose, formulation, and patient factors. Fractional absorption decreases with increasing iron stores due to regulatory mechanisms involving hepcidin, which negatively modulates ferroportin activity, reducing enterocyte iron export into plasma.

Distribution:
Once absorbed, ferrous iron is immediately oxidized to ferric form and bound to transferrin, the major plasma iron transport protein, which delivers iron to bone marrow and other tissues requiring iron for hemoglobin synthesis and cellular functions. Iron is stored intracellularly mainly in ferritin and hemosiderin aggregates, particularly in the liver, spleen, and bone marrow. The volume of distribution is relatively small as iron predominantly binds to transferrin and storage proteins, and excess free iron is rapidly taken up to prevent toxic free radical formation. The dynamic balance between plasma iron bound to transferrin and storage pools regulates systemic iron availability.

Metabolism:
Iron itself is not metabolized chemically but is processed via redox cycling between ferrous (Fe2+) and ferric (Fe3+) states within biological systems. Once absorbed, the iron released from ferrous sulfate dissociates from the salt, binds to transferrin, and participates in erythropoiesis and cellular metabolism. Excess iron is sequestered intracellularly in ferritin to prevent oxidative damage. Hepcidin, a hepatic hormone, tightly controls iron homeostasis by limiting iron egress from enterocytes, macrophages, and hepatocytes, thus regulating systemic iron turnover. Dysregulation of hepcidin production results in iron overload or deficiency.

Elimination:
There is no active excretory pathway for iron; elimination chiefly occurs via sloughing of gastrointestinal mucosal cells, skin desquamation, and minor urinary losses. Daily iron loss is minimal, approximately 1 mg in men and non-menstruating women, but can be higher in menstruating females and during pathological bleeding. Because iron elimination is tightly controlled and minimal, iron homeostasis primarily relies on regulated absorption. In cases of iron overdose, excess unabsorbed iron in the gastrointestinal tract can cause local toxicity and systemic toxicity following absorption of large amounts, especially in pediatric populations.

Dosage Forms

Available Dosage Forms:
- Oral tablet: Ferrous sulfate tablets typically contain 325 mg of ferrous sulfate equivalent to approximately 65 mg of elemental iron.
- Oral liquid: Ferrous sulfate oral liquid formulations are available, with common concentrations such as 160 mg per 5 mL.

Dosages for Adults and Adolescents:
- The usual adult dose for iron deficiency treatment is 325 mg ferrous sulfate tablets (approximately 65 mg elemental iron) taken one to three times daily depending on severity of deficiency and hemoglobin response.
- Liquid formulations allow flexible dosing especially in patients with swallowing difficulties or pediatric populations, dosing typically based on elemental iron requirements, for example 150-300 mg elemental iron daily in divided doses.

Specific Patient Populations:
- Pediatric patients require cautious dosing due to the risk of iron toxicity; often, dosing is weight-based and should always be guided by a healthcare professional.
- Pregnant or breastfeeding women may require adjusted dosing for increased iron demands but should use under medical supervision.
- Patients with conditions such as thalassemia or iron overload syndrome should avoid iron supplementation or use it under strict monitoring.

Clinical guidelines recommend administering ferrous sulfate on an empty stomach to maximize absorption while monitoring for gastrointestinal side effects. Dose adjustments should be made based on laboratory measurements of hemoglobin, hematocrit, and ferritin levels to avoid iron overload.

Mechanism Of Action

Ferrous sulfate acts as an iron replacement therapy by providing bioavailable ferrous ions (Fe2+) that replenish body iron stores essential for multiple physiological functions. The elemental iron in ferrous sulfate is absorbed through the intestinal mucosa primarily by divalent metal transporter 1 (DMT1), allowing iron entry into enterocytes. From there, iron is transported across the basolateral membrane by ferroportin, entering circulation bound to transferrin for distribution.

Within the body, iron is crucial for hemoglobin synthesis in erythroid precursor cells, allowing red blood cells to transport oxygen efficiently. Iron is also involved in myoglobin function in muscle cells for oxygen storage and in various cytochromes and enzymes fundamental to cellular respiration and energy production.

The molecular mechanism entails iron serving as a prosthetic group in heme and non-heme proteins. It readily undergoes redox cycling between ferrous and ferric states, facilitating electron transfer reactions critical in oxidative phosphorylation within mitochondria. This biochemical activity underscores iron's pivotal role in supporting tissue oxygenation and metabolism.

Clinically, ferrous sulfate supplementation corrects iron deficiency anemia by restoring effective erythropoiesis and improving oxygen transport capacity. Compared with other iron formulations, ferrous sulfate offers a balance of efficacy and tolerability despite gastrointestinal side effects. Research indicates that the bioavailability of ferrous sulfate is superior to some ferric salts due to its solubility and absorption characteristics, which are modulated by gastric pH and the presence of dietary factors.

Pharmacological Actions

Replenishes systemic iron stores essential for hematopoiesis.
Supports hemoglobin synthesis in red blood cell precursors.
Enhances oxygen transport capacity of the blood via hemoglobin incorporation.
Facilitates oxygen storage in muscle cells through myoglobin.
Participates as a cofactor in mitochondrial electron transport and cellular energy metabolism.
Acts as an essential element in enzyme function including those involved in DNA synthesis and repair.
Corrects iron deficiency anemia by enabling effective erythropoiesis.
Improves symptoms of anemia such as fatigue, pallor, and dyspnea by restoring oxygen-carrying capacity.
Modulates redox reactions through iron’s ability to shift between ferrous and ferric states.
Interacts with and is regulated by hepcidin to maintain iron homeostasis.
Contributes to immune function by supporting proliferative capacity of immune cells.
Promotes normal growth and development, particularly in pediatric patients with iron deficiency.
Balances iron levels to prevent both deficiency and iron overload conditions.
Demonstrates better bioavailability compared to some ferric iron salts due to solubility and transport mechanisms.
Can induce vascular smooth muscle cell proliferation in pathological states when present in excess.

Therapeutic Or Clinical Uses

Treatment of iron deficiency anemia due to inadequate dietary intake or chronic blood loss.
Prevention of iron deficiency in at-risk populations such as pregnant women, infants, and adolescents.
Management of anemia in patients with chronic kidney disease requiring iron supplementation.
Correction of iron deficiency related to malabsorption syndromes or gastrointestinal surgery.
Supportive therapy during pregnancy to meet increased iron demands.
Treatment of iron deficiency anemia secondary to heavy menstrual bleeding.
Adjunctive therapy in patients receiving erythropoiesis-stimulating agents to enhance response.
Supplementation in patients with chronic inflammatory disorders where iron sequestration occurs.
Management of nutritional anemia in vegetarians or populations with limited iron-rich food sources.
Treatment of anemia prior to elective surgical procedures to reduce transfusion requirements.
Pediatric iron deficiency treatment using liquid formulations for easier administration.
Prophylactic use in premature infants to prevent anemia of prematurity.
Correction of iron deficiency following acute or chronic hemorrhagic events.
Supporting recovery from iron deficiency related to gastrointestinal or genitourinary bleeding.
Off-label use in conditions with increased iron turnover needing repletion.

Side Or Adverse Effects

Gastrointestinal irritation leading to nausea and stomach pain.
Constipation or diarrhea as common gastrointestinal adverse effects.
Greenish discoloration of stools due to unabsorbed iron.
Loss of appetite and general gastrointestinal discomfort.
Rare severe allergic reactions manifesting as hives, facial swelling, or difficulty breathing.
Severe stomach pain or vomiting indicating possible intolerance or toxicity.
Black, tarry stools suggestive of gastrointestinal bleeding.
Fever potentially indicating inflammatory or allergic response.
Vomiting with blood or cough with bloody sputum as signs of hemorrhagic complications.
Iron overdose symptoms including muscle cramps, dizziness, fainting, and dry skin.
Metallic taste following oral administration.
Potential staining of teeth with liquid formulations if not administered properly.
Rare cases of anaphylaxis especially with intravenous formulations (though not applicable to FeroSul).
Local gastrointestinal mucosal injury leading to erosions or ulcers with chronic use.
Secondary iron overload if used inappropriately or in patients with hereditary hemochromatosis.

Precautions

Use only as directed by a healthcare provider to avoid iron overload.
Take ferrous sulfate on an empty stomach to maximize absorption unless gastrointestinal irritation occurs.
Avoid concomitant use with antacids, calcium supplements, or dairy products within 2-6 hours, as they inhibit absorption.
Use cautiously in patients with gastrointestinal disorders such as ulcers or gastritis.
Monitor iron status parameters periodically to avoid iron toxicity.
Do not use in patients with anemia not caused by iron deficiency without proper diagnosis.
Avoid use in patients with disorders of iron metabolism, such as hemochromatosis or hemosiderosis.
Pregnant or breastfeeding women should use ferrous sulfate only under medical supervision.
Keep out of reach of children due to risk of fatal iron overdose.
Measure liquid doses precisely using calibrated devices to avoid dosing errors.
Instruct patients not to crush or chew tablets to minimize gastrointestinal irritation.
Report any signs of severe gastrointestinal distress or allergic reactions promptly.
Consider potential interactions with other drugs, herbal products, and supplements.
Adjust dosing in patients with renal impairment or chronic diseases affecting iron metabolism.
Counsel patients on potential side effects and the importance of adherence to prescribed regimens.

Warnings

Do not exceed recommended doses as iron overdose can be fatal, especially in children.
Seek emergency help immediately in cases of suspected overdose.
Use with caution in patients with iron overload syndromes and red blood cell disorders like thalassemia.
Potential for severe gastrointestinal adverse effects including bleeding or ulceration.
Risk of anaphylaxis though rare with oral formulations; immediate medical attention required if allergic symptoms occur.
May cause false positive stools for blood due to iron content.
Avoid concomitant use with other iron supplements unless prescribed.
Not to be used as a substitute for a balanced diet; dietary sources should be optimized.
Discontinue if severe gastrointestinal adverse effects persist despite supportive measures.
Inspect for proper storage to prevent degradation from moisture or heat.
Inform healthcare providers of all medications to prevent drug interactions.
Not recommended in patients with known hypersensitivity to ferrous sulfate compounds.
Use in pregnancy only if benefits outweigh potential risks; monitor fetal development.
Avoid use in patients with active peptic ulcer disease until resolved.
Use cautiously in elderly patients who may be more susceptible to adverse effects.

Contraindication

Known hypersensitivity to ferrous sulfate or any component of the formulation.
Hemochromatosis or other iron overload disorders.
Hemolytic anemia unrelated to iron deficiency.
Patients with anemia not caused by iron deficiency without definitive diagnosis.
Severe peptic ulcer disease or gastritis due to risk of mucosal injury.
Patients with acute iron poisoning or conditions with increased risk of iron toxicity.
Children under medical supervision only; dosing contraindicated in accidental ingestion due to risk of fatal overdose.
Patients receiving chronic blood transfusions leading to iron overload.
Use contraindicated if patient history reveals iron-induced anaphylactic reactions.
Severe hepatic impairment where iron metabolism may be compromised.
Patients with active gastrointestinal bleeding without appropriate management.
Concomitant use of other oral iron products unless under medical instruction.
Contraindicated in individuals with significant inflammation-mediated anemia where iron sequestration dominates.
Patients with genetic disorders of iron transporter proteins causing accumulation.
Contraindicated if tablet cannot be swallowed whole due to potential for mucosal damage if broken.

Drug Interactions

Antacids containing magnesium or aluminum reduce ferrous sulfate absorption if administered simultaneously.
Calcium supplements decrease iron absorption when taken concomitantly; separate dosing by at least 2-6 hours.
Laxatives may affect gastrointestinal transit time, impacting absorption.
Certain antibiotics such as doxycycline, tetracycline, and fluoroquinolones form chelates with iron, reducing absorption of both agents.
Vitamin C can enhance iron absorption by maintaining iron in the reduced ferrous form.
Cholestyramine can decrease iron absorption by binding bile acids and affecting gastrointestinal environment.
Thyroid medications’ absorption may be diminished when taken with ferrous sulfate.
Levodopa and Parkinson’s disease medications may have altered efficacy due to iron interactions.
Penicillamine efficacy is reduced because of chelation with iron ions.
Iron may increase the risk of toxicity of methotrexate by unknown mechanisms.
Iron supplements can interfere with serum assays for fecal occult blood tests leading to false positives.
Iron can enhance the absorption of certain chemotherapeutic agents leading to increased toxicity.
Concurrent use with antiretroviral agents such as didanosine requires monitoring for reduced efficacy.
Herbal products like tannin-containing teas can reduce iron bioavailability by forming insoluble complexes.
Iron may impair the absorption of levothyroxine necessitating dose adjustment and staggered administration.

Preparations Of The Drug

Ferrous sulfate oral tablets, typically 325 mg containing about 65 mg elemental iron.
Ferrous sulfate oral liquid preparations with concentrations such as 160 mg elemental iron per 5 mL.
Slow-release formulations providing extended iron release to mitigate gastrointestinal side effects.
Chewable tablets available for those with swallowing difficulties, although care should be taken to avoid choking hazards.
Sugar-coated tablets designed to mask metallic taste and improve patient compliance.
Drops formulated for infants and toddlers to accurately dose smaller quantities.
Combination products containing ferrous sulfate with vitamins such as vitamin C to enhance absorption.
Parenteral iron formulations exist (e.g., iron dextran or iron sucrose) but are distinct from ferrous sulfate oral preparations.
Liquid suspensions formulated with flavoring agents for better palatability in pediatric populations.
Multivitamin preparations with included ferrous sulfate tailored for supplementation in pregnancy.
Effervescent tablets designed for rapid dissolution in liquids allowing easier ingestion.
Film-coated tablets to reduce direct mucosal irritation.
Generic equivalents available following discontinuation of the branded FeroSul.
Preparation instructions emphasize storage at room temperature, away from moisture and heat.
Packaging includes dosing syringes for liquid forms to ensure accurate and safe administration.